Physician profile
Patrick Michael Long
NPI 1740676683
$4,444.93
in general payments reported to CMS, 2019-2025
12 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,122 · 2022: $1,172 · 2023: $124 · 2024: $529 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,293.57 | 2021-2022 | |
| Genzyme Corporation | $583.88 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $152.25 | 2023-2025 | Onpattro, Amvuttra, Oxlumo |
| Alexion Pharmaceuticals, INC. | $134.99 | 2025 | Strensiq |
| Amgen INC. | $74.64 | 2024 | Ravicti |
| Takeda Pharmaceuticals U.S.A., INC. | $51.16 | 2023-2024 | |
| Springworks Therapeutics, INC. | $33.09 | 2025 | Gomekli |
| Astrazeneca Pharmaceuticals LP | $31.46 | 2025 | Wainua |
| Pharming Healthcare, INC. | $26.91 | 2024 | Ruconest |
| Biomarin Pharmaceutical INC. | $23.23 | 2024 | Palynziq |
| Mirum Pharmaceuticals, INC. | $23.01 | 2024 | Cholbam |
| Biogen, INC. | $16.74 | 2025 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.